Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents
de Oliveira L, de Morais I, Marchioro S, de Almeida G, de Almeida de Souza G, da Silva Ferreira T, Rossoni R, de Oliveira Barbosa D, Navarini V, Croda J, Torres A, Simionatto S. Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents. Vaccine 2024, 43: 126494. PMID: 39571350, DOI: 10.1016/j.vaccine.2024.126494.Peer-Reviewed Original ResearchCD8+ T cellsBNT162b2 vaccineT cellsB lymphocytesIncreased levels of B lymphocytesImmune responseCell subpopulationsLevels of B lymphocytesSARS-CoV-2-specific immune responsesMemory B cellsNon-classical monocytesIndigenous adolescentsStatistically significant increaseNK cellsVaccinated adolescentsB cellsNo significant changesBooster doseCohort studyBNT162b2Vaccination scheduleLimited healthcare resourcesImmunogenic responseDemographic dataCOVID-19 vaccineFactors influencing adverse events following COVID-19 vaccination
Villanueva P, McDonald E, Croda J, Croda M, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Lynn D, Marshall H, Oliveira R, Rocha J, Sawka A, Val F, Pittet L, Messina N, Curtis N. Factors influencing adverse events following COVID-19 vaccination. Human Vaccines & Immunotherapeutics 2024, 20: 2323853. PMID: 38445666, PMCID: PMC10936640, DOI: 10.1080/21645515.2024.2323853.Peer-Reviewed Original ResearchConceptsVaccine typesSystemic reactionsIncidence of AEFIAdverse eventsVaccine doseIncidence of adverse eventsCovid-19 specific vaccineCOVID-19 vaccineNested cohort studyIgG antibody responsesRisk of AEFICOVID-19 vaccine typesChAdOx1 recipientsBNT162b2 recipientsCohort studyPfizer-BioNTechCoronaVac vaccineAntibody responseChAdOx1Oxford-AstraZenecaCoronaVacBNT162b2Local reactionsDoseDevelopment of COVID-19 vaccines